SecBot SecBot
8-K ·Filed Feb 25, 2026

SRPT

Sarepta Therapeutics, Inc.
MIXED
Impact 7/10
Horizonmonths Processed8mo ago SEC0001193125-26-071566
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

Monitor ELEVIDYS sales recovery in 2026, especially with Japan launch and potential pathway back to serving non-ambulatory patients. Watch for updated guidance on profitability and cash flow sustainability. The strong pipeline data and financial restructuring provide long-term upside, but near-term execution on commercial recovery is key.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$17.45
T+0 close · Feb 25, 2026 · via day close
Latest settled
−3.72%
T+60 · $16.80
Vs SPY
−11.90%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 26 $17.45entry
  2. T+1 · 9mo ago −3.95%α −3.47% · $16.76
  3. T+5 · 9mo ago −6.99%α −5.83% · $16.23
  4. T+20 · 8mo ago +24.24%α +30.65% · $21.68
  5. T+60 · 6mo ago −3.72%α −11.90% · $16.80
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Sarepta Therapeutics reported mixed financial results for 2025, with full-year revenue growing 16% to $2.20 billion driven by ELEVIDYS and collaboration revenue, but Q4 revenue declining 33% due to suspended shipments of ELEVIDYS to non-ambulatory patients. The company strengthened its financial position through debt refinancing and expects to remain profitable and cash-flow positive in 2026, while advancing its pipeline including positive three-year ELEVIDYS data and Japan launch.

Key Financial Metrics

Revenue
$2.2B
+15.6% YoY
Adj. EPS
$-5.05
GAAP: $-7.13

Key Facts

  • Full-year 2025 revenue was $2.198 billion, up 16% YoY, driven by $77.9 million increase in ELEVIDYS net product revenue and $219.9 million in higher collaboration revenue
  • Q4 2025 revenue was $442.9 million, down 33% YoY, primarily due to $273.8 million less in ELEVIDYS net product revenue after suspending shipments to non-ambulatory patients
  • GAAP net loss was $713.4 million for 2025 vs. $235.2 million profit in 2024, with Q4 2025 GAAP net loss of $412.2 million vs. $159.0 million profit in Q4 2024
  • Cash, cash equivalents, restricted cash and investments were $953.8 million as of December 31, 2025, down from $1.50 billion as of December 31, 2024
  • Positive three-year EMBARK study data showed ELEVIDYS maintained motor function above baseline while control group declined, with 73% slowing of disease progression in Time to Rise and 70% in 10-meter walk/run
  • ELEVIDYS launched in Japan in February 2026, with Sarepta eligible for a $40 million milestone payment upon first commercial sale
  • Company refinanced $291.4 million of 2027 convertible notes into new 2030 notes plus $31.6 million cash, leaving only $158.6 million of original notes outstanding

Financial Impact

Revenue grew 16% to $2.20B for full year 2025 but declined 33% to $442.9M in Q4; net loss widened to $713.4M for 2025 from $235.2M profit in 2024

revenueepscashFlow

Segment Breakdown

SegmentRevenue
PMO$965.6M
ELEVIDYS$898.7M

Risk Factors

  • Q4 revenue decline due to ELEVIDYS shipment suspension to non-ambulatory patients
  • Widening net loss despite revenue growth, raising sustainability concerns
  • Decline in cash position from $1.50B to $953.8M year-over-year

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-071566
Document: srpt-20260225.htm0001193125-26-071566
Document: 0001193125-26-071566-index-headers.html0001193125-26-071566
Document: 0001193125-26-071566-index.html0001193125-26-071566
Document: 0001193125-26-071566.txt0001193125-26-071566

US Market Status

Market Closed · Opens in 8h 30m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 25, 2026